FSD Pharma Brief: FDA and Health Canada Clear IND for FSD Pharma to Proceed With Phase 2 Trial of FSD201 for Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome
FSD Pharma Brief: FDA and Health Canada Clear IND for FSD Pharma to Proceed With Phase 2 Trial of FSD201 for Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome
FSD Pharma Brief：FDA和加拿大衞生部批准FSD Pharma繼續進行FSD201治療與特發性肥大細胞激活綜合徵相關的腫瘤性疼痛的第二階段試驗
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊